Table 1. Clinical trials of epigenetic drugs in prostate cancer.

Drug	Combined Therapy	Enzimatic Class	Approval Stage	Status	Indication	Results	Reference/Clinical trial identification
SB939	-	HDAC inhibitor	Phase 2	Completed	Castration Resistance Prostate Cancer (CRPC)	6% of the patients had a PSA response64% of the patients had a conversion from an unfavorable CTC profile to a favorable one	Eigl et al. 2015 (NCT01075308)
Panobinostat	-	HDAC inhibitor	Phase 2	Completed	CRPC	14,3% of the patients had a PSA decrease <50% but no objective responses were seen 11,4% of the patients had stable disease for at least 24 weeks	Rathkopf et al. 2013 (NCT00667862)
Panobinostat	Docetaxel	HDAC inhibitor	Phase 1	Completed	CRPC	63% had a PSA decrease >= 50%	Rathkopf et al. 2010
Panobinostat	Radiotherapy	HDAC inhibitor	Phase 1	Completed	Prostate Cancer, esophageal cancer and neck cancer	No study results or publications provided	NCT00670553
Panobinostat	Docetaxel/prednisone	HDAC inhibitor	Phase 2	Completed	CRPC	No study results or publications provided	NCT00878436
Panobinostat	Bicalutamide	HDAC inhibitor	Phase 1	Completed	CRPC	No study results or publications provided	NCT00663832
Vorinostat	-	HDAC inhibitor	Phase 2	Completed	Progressive metastatic prostate cancer	No PSA declines >=50% were observed Median of progression free survival=2,8 months with a median overall survival of 11,7 months	Bradley et al. 2010 (NCT00330161)
Vorinostat	Docetaxel	HDAC inhibitor	Phase 1	Terminated	Advanced solid tumor including prostate cancer, urothelial carcinoma and kidney cancer	This study was terminated due to excessive toxicity as five patients experienced dose-limiting toxicities (DLT) No responses were observed	Schneider et al. 2012 (NCT00565227)
Vorinostat	Temsirolimus	HDAC inhibitor	Phase 1	Terminated	Metastatic prostate cancer	This study was terminated due to lack of efficacy	NCT01174199
Vorinostat	Androgen deprivation therapy	HDAC inhibitor	Phase 2	Completed	Localized prostate cancer	No study results or publications provided	NCT00589472
Vorinostat	-	HDAC inhibitor	Phase 1	Completed	Advanced solid tumors including prostate cancer	No study results or publications provided	NCT00005634
Romidepsin	-	HDAC inhibitor	Phase 2	Completed	Metastatic prostate cancer	No study results or publications provided	NCT00106418
Romidepsin	-	HDAC inhibitor	Phase 2	Completed	metastatic castration-resistant prostate cancer (MCRPC)	63% of the patients had progressive disease with a median time to progression of 49,5 daysPSA decline >=50% was observed in 5,7% of the patients	Molife et al. 2009
Curcumin	Docetaxel	HDAC inhibitor	Phase 2	Ongoing	MCRPC	Final data collection date for primary outcome measure: January 2017	NCT02095717
Curcumin	-	HDAC inhibitor	Phase 2	Ongoing	Prostate cancer	Estimated primary completion date: June 2020	NCT02064673
Curcumin	Radiotherapy	HDAC inhibitor	-	Completed	Prostate cancer	No PSA response was observed but the severity of radiotherapy related urinary symptoms was reduced,	Hejazi J. et al. 2013
Dissulfiram	-	DNMT inhibitor	Phase 1	Completed	Non-metastatic recurrent prostate cancer	Five patients achieve a transient demethylation response Six patients discontinue therapy due to adverse effects	Schweizer et al. 2013
Azacitidine	Combined Androgen Blockade (CAB)	DNMT inhibitor	Phase 2	Completed	CRPC	Overall median PSA doubling time increased significantly (2.8 vs 1.5 months of the baseline).Median of progression free survival=12,4 weeksFourteen patients had some PSA decline and 1 patient had a PSA decline >=30%	Sonpavde et al. 2011
Azacitidine	-	DNMT inhibitor	Phase 2	Completed	Prostate cancer	No study results or publications provided	NCT00384839
Azacitidine	Docetaxel/prednisone	DNMT inhibitor	Phase1/2	Terminated	CRPC	This study was terminated due to withdrawal of funding Complete and partial response were achieved by one and two patients, respectively	NCT00503984